Protagenic Therapeutics Faces Nasdaq Delisting Due to Compliance Issues

MT Newswires Live
2025/11/28

Protagenic Therapeutics (PTIX) said Thursday it received a Nasdaq notice for failing to meet the minimum $2.5 million stockholders' equity requirement and for not filing its quarterly report on time.

The company said Nasdaq flagged its recently reported equity levels and the delayed Form 10-Q for the quarter ended Sept. 30, 2025. Because the company had only recently regained compliance and remains under a mandatory panel monitoring period, Nasdaq has moved to delist its shares.

The company said it will request a hearing, which automatically halts any suspension for 15 days, and will also seek an additional stay while the panel reviews its case.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10